D89.44
D89.44: Hereditary alpha tryptasemia
Billable / specific codeICD-10-CM
D89.44 is a billable, specific ICD-10-CM code for hereditary alpha tryptasemia. It is valid for submission on a claim.
Check D89.44 with the rest of the claim: free scrubberUse additional code
Add a secondary code to capture the detail described below.
Excludes1 inherited from the categories above D89.44
A category’s note binds every code beneath it.
Written on D89.4: Mast cell activation syndrome and related disorders
- aggressive systemic mastocytosis (C96.21)
- congenital cutaneous mastocytosis (Q82.2)
- (non-congenital) cutaneous mastocytosis (D47.01)
- (indolent) systemic mastocytosis (D47.02)
- malignant mast cell neoplasm (C96.2-)
- malignant mastocytoma (C96.29)
- mast cell leukemia (C94.3-)
- mast cell sarcoma (C96.22)
- mastocytoma NOS (D47.09)
- other mast cell neoplasms of uncertain behavior (D47.09)
- systemic mastocytosis associated with a clonal hematologic non-mast cell lineage disease (SM-AHNMD) (D47.02)
Excludes2 inherited from the categories above D89.44
Not part of this code, but both may be coded when both are present.
Risk adjustment
No CMS-HCC V28 category: this code does not change a RAF score.
Medicare coverage
D89.44 is named in 4 Medicare coverage policies: 4 listing it as supporting medical necessity. Which one applies depends on your Medicare contractor.
- A58710Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
- A58720Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
- A58747Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
- A58761Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing
Alphabetic index entries that lead here
- Hereditary alpha tryptasemia(syndrome)
- Tryptasemia, hereditary alpha
- Syndrome›hereditary alpha tryptasemia
Code history
Unchanged in every release from FY2024 to FY2027.